Subcutaneous fat necrosis of the newborn

Sven Schulzke, Stanislav Bückner, Hubert Fahnentich

1 Department of Neonatology, University Children’s Hospital, Basel, Switzerland
2 Department of Dermatology, University Hospital, Basel, Switzerland

We report on a term girl born by urgent caesarean section due to variable foetal decelerations during labour. Weight 3830 g, Apgar scores 4/6/8 (1/5/10') and arterial umbilical cord pH 6.89. Suffering a mild respiratory distress syndrome for the first day of life with a maximum FiO2 of 0.3, she was transferred to the neonatal intensive care unit. Transient arterial hypotension down to 29 mm Hg mean arterial pressure was rapidly corrected by two intravenous bolus administrations of 0.9% saline solution. Initially the capillary blood gases showed metabolic acidosis (pH 7.14, PCO2 30 mm Hg, BE −18 mmol/l), but recovered completely and spontaneously within 12 hours of life. No body surface cooling was applied. The neurological findings after 24 hours of life were normal and breast feeding was started on day 2 without problems. Cranial ultrasound including doppler studies on day 2 revealed no signs of cerebral oedema or bleeding. The child was discharged to maternity in good health on day 5, but was readmitted on day 6 with obviously painful, firm, large erythematous nodules and plaques on her back, dorsal neck and upper arms (fig. 1). She was placed in the prone position and received paracetamol. Histological examination of a biopsy specimen from a nodule on her back revealed patchy fat necrosis with fat crystallisation. In addition, macrophages and foreign-body giant cells, neutrophils, lymphocytes and eosinophils were present in the inflammatory infiltrate (fig. 2). These findings were consistent with the diagnosis of subcutaneous fat necrosis of the newborn (SCFN). Additional diagnostic workup showed normal serum calcium levels of 2.2–2.6 mmol/l (1.3–1.6 mmol/l ionised calcium), no thrombocytopenia and no hyperlipidaemia. Starting on day 16, the cutaneous lesions gradually decreased in size and intensity, were less erythematous and no longer painful. The newborn was finally discharged home. At 12 weeks of age the cutaneous symptoms had resolved. She did not develop hypercalcaemia in the first year of life and neurological follow-up was excellent.

Discussion

SCFN involves painful, firm, erythematous nodules and plaques over the trunk, arms, buttocks, thighs, and cheeks of full-term newborns. No epidemiological data are available for SCFN. Lesions appear in the first or second month of life and resolve within several weeks to months. A granulomatous infiltrate is formed subsequently. Lesions may calcify, and non-renal absorption of calcium increases. The exact pathophysiology of SCFN is unknown. Perinatal distress, as in asphyxia, meconium aspiration or hypothermia, followed by skin hypoperfusion, may lead to subcutaneous fat necrosis [1]. In the context of localised inflammation, mobilised calcium from the necrosis and elevated vitamin D levels, hypercalcaemia may occur [2]. Both the direct application of ice packs on the skin to treat supraventricular tachycardia and induced hypothermia in cardiac surgery are other factors which may lead to this condition [3, 4].

SCFN is a self-limiting disease but may be complicated by hyperlipidaemia, transient thrombocytopenia and, more commonly, severe hypercalcaemia [1]. Thrombocytopenia appears to occur concomitantly with the cutaneous symptoms and there are no reports of severe bleeding. Hypercalcaemia may occur after several weeks and result in seizures, blindness and even death due to infection or cardiac arrest [5, 6].

To be considered in differential diagnosis are sclerema neonatorum, histiocytosis and cellulois; conditions such as erythema nodosum, lipogranulomatosis (Farber disease), neurofibroma or sarcoma should be ruled out. Diagnosis of SCFN usually requires a deep skin biopsy since it may be difficult to exclude sclerema neonatorum, which carries a mortality rate of 75% while the prognosis of SCFN is good [1, 7]. Histology shows patchy areas of fat necrosis surrounded by a granulomatous infiltrate of lymphocytes, macrophages and giant cells. Many of the fat and giant cells contain needle-shaped clefts often in a radial arrangement [8].

Treatment of SCFN consists of analgesia. If hypercalcaemia occurs it may require aggressive treatment. Empirical baseline treatment is fluid loading, termination of vitamin D substitution and a low calcium diet, together with diuretics such as furosemide to decrease oral calcium intake and increase renal calcium output [9]. If these measures do not maintain a normal calcium level, 1–2 mg/kg/d prednisone is used to control the granulomatous inflammatory process and lower vitamin D production [9]. Since hypercalcaemia may occur after several weeks and last for months, periodic checks on serum calcium are necessary in the first 3–6 months of life. Parents should be informed of the signs of hypercalcaemia such as failure to thrive, hypotonia and vomiting, and urged to contact their paediatrician if any should appear.

Newborn animal and small human pilot studies suggest that mild hypothermia following peripartum hypoxia-ischaemia in newborn infants may reduce neurological seque-
Correspondence:
Dr. Sven Schulzke
University Children’s Hospital Basel
Roemergasse 8
CH-4005 Basel
sven.schulzke@unibas.ch

References
The many reasons why you should choose SMW to publish your research

*What Swiss Medical Weekly has to offer:*

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

*Editorial Board*

- Prof. Jean-Michel Dayer, Geneva
- Prof. Peter Gehr, Berne
- Prof. André P. Perruchoud, Basel
- Prof. Andreas Schaffner, Zurich
  (Editor in chief)
- Prof. Werner Straub, Berne
- Prof. Ludwig von Segesser, Lausanne

*International Advisory Committee*

- Prof. K. E. Juhani Airaksinen, Turku, Finland
- Prof. Anthony Bayes de Luna, Barcelona, Spain
- Prof. Hubert E. Blum, Freiburg, Germany
- Prof. Walter E. Haefeli, Heidelberg, Germany
- Prof. Nino Kuenzli, Los Angeles, USA
- Prof. René Lutter, Amsterdam, The Netherlands
- Prof. Claude Martin, Marseille, France
- Prof. Josef Patsch, Innsbruck, Austria
- Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

*Guidelines for authors:*
http://www.smw.ch/set_authors.html

*Impact factor Swiss Medical Weekly*

![Impact factor chart]

*EMH Schweiz Med Wochenschr (1871–2000)*

*EMH Schweiz Med Wkly (continues Schweiz Med Wochenschr from 2001)*

*All manuscripts should be sent in electronic form, to:*

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch